PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

1 . A conjugate of formula

ConjB:

ConjC

or

ConjDE:

wherein:

Ab is an antibody that binds to HER2, the antibody comprising a VH domain having the sequence according to SEQ ID NO. 1.

2 . The conjugate according to claim 1 wherein the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences of SEQ ID NO. 1 paired with SEQ ID NO. 2.

3 . The conjugate according to claim 1 wherein the antibody in an intact antibody.

4 . The conjugate according to claim 3 wherein the antibody comprises a heavy chain having the sequence of SEQ ID NO. 3 paired with a light chain having the sequence of SEQ ID NO. 4.

5 . The conjugate according to claim 4 wherein the antibody comprises two heavy chains having the sequence of SEQ ID NO. 3, each paired with a light chain having the sequence of SEQ ID NO. 4.

6 . The conjugate according to claim 1 wherein the antibody is humanised, deimmunised or resurfaced.

7 . The conjugate according to claim 1 wherein the drug loading (p) of drugs (D) to antibody (Ab) is an integer from 1 to about 8.

8 . The conjugate according to claim 7 , wherein p is 1, 2, 3, or 4.

9 . The conjugate according to claim 7 comprising a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.

10 .- 12 . (canceled)

13 . A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable diluent, carrier or excipient.

14 . The pharmaceutical composition of claim 13 further comprising a therapeutically effective amount of a chemotherapeutic agent.

15 . (canceled)

16 . A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 13 .

17 . The method of claim 16 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.